"VSports手机版" Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The VSports app下载. gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

. 2014 Jan;31(1):101-10.
doi: 10.1007/s10585-013-9614-5. Epub 2013 Sep 5.

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

Dana M Roque  1 , Natalia Buza, Michelle Glasgow, Stefania Bellone, Ileana Bortolomai, Sara Gasparrini, Emiliano Cocco, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Thomas J Rutherford, Peter E Schwartz, Alessandro D Santin
Affiliations

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel (VSports在线直播)

Dana M Roque et al. Clin Exp Metastasis. 2014 Jan.

Abstract

Critics have suggested that neoadjuvant chemotherapy (NACT) followed by interval debulking may select for resistant clones or cancer stem cells when compared to primary cytoreduction. β-tubulins are chemotherapeutic targets of taxanes and epothilones. Class III β-tubulin overexpression has been linked to chemoresistance and hypoxia. Herein, we describe changes in class III β-tubulin in patients with advanced ovarian carcinoma in response to NACT, in relationship to clinical outcome, and between patients who underwent NACT versus primary debulking; we characterize in vitro chemosensitivity to paclitaxel/patupilone of cell lines established from this patient population, and class III β-tubulin expression following repeated exposure to paclitaxel. Using immunohistochemistry, we observed among 22 paired specimens obtained before/after NACT decreased expression of class III β-tubulin following therapy within stroma (p=0. 07), but not tumor (p=0. 63). Poor median overall survival was predicted by high levels of class III β-tubulin in both tumor (HR 3. 66 [1 VSports手机版. 11,12. 05], p=0. 03) and stroma (HR 4. 53 [1. 28,16. 1], p=0. 02). Class III β-tubulin expression by quantitative-real-time-polymerase-chain-reaction was higher among patients who received NACT (n=12) compared to primary cytoreduction (n=14) (mean±SD fold-change: 491. 2±115. 9 vs. 224. 1±55. 66, p=0. 037). In vitro subculture with paclitaxel resulted in class III β-tubulin upregulation, however, cell lines that overexpressed class III β-tubulin remained sensitive to patupilone. Overexpression of class III β-tubulin in patients dispositioned to NACT may thus identify an intrinsically aggressive phenotype, and predict poor overall survival and paclitaxel resistance. Decreases in stromal expression may represent normalization of the tumor microenvironment following therapy. Epothilones warrant study for patients who have received neoadjuvant carboplatin and paclitaxel. .

PubMed Disclaimer

"V体育2025版" Conflict of interest statement

CONFLICT OF INTEREST STATEMENT

The authors have no conflicts of interest to declare.

Figures

Fig 1
Fig 1
Following treatment with NACT, a trend towards decreased strength of stromal (p = 0.07) but not tumoral staining (p = 0.76) was observed. Horizontal bars represent mean values
Fig 2
Fig 2
Following NACT, class III β-tubulin staining by immunohistochemistry was unchanged in tumor, but decreased in surrounding stroma. Representative slides are shown at original magnification of 100–200x and illustrate 3+ stromal staining before NACT (left) and 1+ stromal staining after NACT (middle); corresponding scores for tumor staining in this specimen are 3+ and 2+, respectively. Normal ovary does not stain for class III β-tubulin (right)
Fig 3
Fig 3
a Class III β-tubulin staining by both tumor (left) and stroma (right) predicts crude overall survival (OS). Median OS among patients with high [2+,3+] versus low [0,1+] expression by tumor was 707 days versus not reached (HR 3.66 [1.11,12.1], p=0.03). Similarly, median OS among patients with high [1+,2+,3+] versus low [0] expression by stroma was 649 versus 1494 days (HR 4.53 [1.28,16.1], p=0.02). b Decreased expression of class III β-tubulin expression following NACT in both tumor (ΔIHC score ≤ 1 vs ≥ 0: not reached vs 707 days, HR 2.116 [0.58, 7.69], p = 0.25) (left) and stroma (ΔIHC score ≤ −1 vs ≥ 0: 1494 vs 596 days, HR 2.73 [0.693, 10.72], p= 0.15) (right) appeared to confer survival benefit, though statistical significance was not reached
Fig 4
Fig 4
Patients dispositioned to NACT exhibit higher class III β-tubulin levels compared to those who undergo primary debulking. At time of cytoreduction, among 12 patients treated with NACT and 14 who underwent primary debulking class III β-tubulin expression values were 491.0 ± 115.7 and 224.1 ± 55.66, respectively
Fig 5
Fig 5
a Paclitaxel subculture of 10 cell lines results in upregulation of class III β-tubulin (from 985.8 ± 219 before treatment to 2306 ± 550 after treatment; p = 0.039). b Characteristics of cell lines exposed to paclitaxel subculture. c Ovarian serous cell lines that overexpress class III β-tubulin are exquisitely sensitive to patupilone; representative chemoresponsiveness to paclitaxel and patupilone among three different chemotherapy-naïve cell lines is shown in relationship to baseline class III β-tubulin expression. Molar concentration (x-axis) is shown against percentage viable cells (y-axis).
See this image and copyright information in PMC

References

    1. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RHM, van der Burg MEL, Lacave AJ, Benedetti-Panici P, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New Engl J Med. 2010;363:943–953. - PubMed
    1. Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol. 2009;16:2315–2320. - PubMed
    1. Crawford SC, Vasey PA, Paul J, Hay A, Kaye SB. Does aggressive surgery only benefit patients with less advanced cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol. 2005;23:8802–8811. - PubMed
    1. Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi DA, Santin AD, Schwartz PE. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV) J Surg Oncol. 2013;107(2):195–200. - PubMed
    1. Menczer J, Usviatzov I, Ben-Shem E, Golan A, Levy T. Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival? J Gynecol Oncol. 2011;22(3):183–187. - PMC - PubMed

MeSH terms

Substances